SG11201810934TA - Microparticles comprising a sulphur-containing compound - Google Patents
Microparticles comprising a sulphur-containing compoundInfo
- Publication number
- SG11201810934TA SG11201810934TA SG11201810934TA SG11201810934TA SG11201810934TA SG 11201810934T A SG11201810934T A SG 11201810934TA SG 11201810934T A SG11201810934T A SG 11201810934TA SG 11201810934T A SG11201810934T A SG 11201810934TA SG 11201810934T A SG11201810934T A SG 11201810934TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- aberdeen
- microparticles
- june
- pct
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Otolaryngology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Accessories For Mixers (AREA)
- Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
- Pigments, Carbon Blacks, Or Wood Stains (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662346969P | 2016-06-07 | 2016-06-07 | |
| GBGB1609940.0A GB201609940D0 (en) | 2016-06-07 | 2016-06-07 | Microparticles |
| PCT/GB2017/051637 WO2017212249A1 (en) | 2016-06-07 | 2017-06-06 | Microparticles comprising a sulphur-containing compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201810934TA true SG11201810934TA (en) | 2019-01-30 |
Family
ID=56508202
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201810934TA SG11201810934TA (en) | 2016-06-07 | 2017-06-06 | Microparticles comprising a sulphur-containing compound |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11369568B2 (enExample) |
| EP (1) | EP3463325B1 (enExample) |
| JP (1) | JP7195934B2 (enExample) |
| KR (1) | KR102412212B1 (enExample) |
| CN (1) | CN109310654A (enExample) |
| AU (1) | AU2017277897B2 (enExample) |
| BR (1) | BR112018075221B1 (enExample) |
| CA (2) | CA3096121C (enExample) |
| DK (1) | DK3463325T3 (enExample) |
| ES (1) | ES2965017T3 (enExample) |
| FI (1) | FI3463325T3 (enExample) |
| GB (1) | GB201609940D0 (enExample) |
| MX (1) | MX2018014278A (enExample) |
| SG (1) | SG11201810934TA (enExample) |
| WO (1) | WO2017212249A1 (enExample) |
| ZA (1) | ZA201807852B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10905660B2 (en) | 2016-06-07 | 2021-02-02 | Novabiotics Limited | Microparticles |
| EP3572068A1 (en) * | 2018-05-22 | 2019-11-27 | RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. | New salt of cysteamine for the preparation of highly respirable particles |
| CA3116637A1 (en) * | 2018-10-17 | 2020-04-23 | Novabiotics Limited | Dosage regime |
| US20230346696A1 (en) * | 2020-09-03 | 2023-11-02 | Philip Morris Products S.A. | Spray dried low hygroscopicity active powder compositions |
| US11793808B2 (en) | 2021-02-22 | 2023-10-24 | Mannkind Corp. | Compositions of clofazimine, combinations comprising them, processes for their preparation, uses and methods comprising them |
| JP2024545086A (ja) * | 2021-12-07 | 2024-12-05 | シラ セラピューティック インコーポレイティッド | 抗ウイルス治療剤及びその使用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8901570D0 (sv) | 1989-05-02 | 1989-05-02 | Draco Ab | Organic salts of cysteine derivatives |
| WO2006071102A1 (en) * | 2004-12-30 | 2006-07-06 | Dobeel Co., Ltd. | Spray-dried composition containing collectin family proteins or variants therof and process for preparing the same |
| AR057623A1 (es) | 2005-11-28 | 2007-12-05 | Omega Bio Pharma H K Ltd | Materiales y metodos para el tratamiento de las infecciones virales |
| KR101433152B1 (ko) | 2006-12-22 | 2014-08-22 | 시그마타우 인두스트리에 파르마슈티케 리우니테 에스.피.에이. | 안과용 약물의 전달에 유용한 젤 |
| CN101342155B (zh) * | 2007-07-11 | 2012-01-04 | 天津帝士力投资控股集团有限公司 | 一种(r,r)-福莫特罗吸入粉雾剂及其制备方法 |
| US20120135969A1 (en) | 2008-11-27 | 2012-05-31 | Boehringer Ingelheim International Gmbh | Novel powdered crystalline medicines for inhalation |
| CA2751386C (en) * | 2009-02-03 | 2018-03-06 | Microbion Corporation | Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications |
| WO2010138419A2 (en) | 2009-05-23 | 2010-12-02 | Obio Pharmaceutical (H.K.) Ltd. | Materials and methods for treating viral infections |
| GB201021186D0 (en) | 2010-12-14 | 2011-01-26 | Novabiotics Ltd | Composition |
| CA2981038C (en) | 2011-05-19 | 2018-09-25 | Savara Inc. | Dry powder vancomycin compositions and associated methods |
| JP5981123B2 (ja) * | 2011-10-11 | 2016-08-31 | サンサ コーポレーション （バルバドス） インク | ニコチン薬の製造法およびその方法により製造される医薬 |
| AU2011379972B2 (en) * | 2011-10-26 | 2016-05-12 | Seattle Children's Research Institute | Cysteamine in the treatment of fibrotic disease |
| JP2015509489A (ja) * | 2012-02-10 | 2015-03-30 | ホワイトヘッド・インスティテュート・フォー・バイオメディカル・リサーチ | がんの処置のためのグリシン開裂系の阻害 |
| ITMI20130572A1 (it) | 2013-04-10 | 2014-10-11 | Eratech Srl | Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione |
| JP6483714B2 (ja) * | 2013-10-11 | 2019-03-13 | ローレンス エス． ジスマン， | 噴霧乾燥製剤 |
| GB201416716D0 (en) | 2014-09-22 | 2014-11-05 | Novabiotics Ltd | Use |
| ITUA20161799A1 (it) * | 2016-03-18 | 2017-09-18 | Recordati Ind Chimica E Farmaceutica S P A | Composizione farmaceutica a rilascio prolungato comprendente cisteamina o un suo sale |
| US10905660B2 (en) * | 2016-06-07 | 2021-02-02 | Novabiotics Limited | Microparticles |
-
2016
- 2016-06-07 GB GBGB1609940.0A patent/GB201609940D0/en not_active Ceased
-
2017
- 2017-06-06 KR KR1020187035476A patent/KR102412212B1/ko active Active
- 2017-06-06 EP EP17735616.9A patent/EP3463325B1/en active Active
- 2017-06-06 WO PCT/GB2017/051637 patent/WO2017212249A1/en not_active Ceased
- 2017-06-06 CA CA3096121A patent/CA3096121C/en active Active
- 2017-06-06 SG SG11201810934TA patent/SG11201810934TA/en unknown
- 2017-06-06 JP JP2018563831A patent/JP7195934B2/ja active Active
- 2017-06-06 FI FIEP17735616.9T patent/FI3463325T3/fi active
- 2017-06-06 CN CN201780035360.7A patent/CN109310654A/zh active Pending
- 2017-06-06 DK DK17735616.9T patent/DK3463325T3/da active
- 2017-06-06 US US16/307,990 patent/US11369568B2/en active Active
- 2017-06-06 BR BR112018075221-5A patent/BR112018075221B1/pt active IP Right Grant
- 2017-06-06 CA CA3026743A patent/CA3026743C/en active Active
- 2017-06-06 MX MX2018014278A patent/MX2018014278A/es unknown
- 2017-06-06 ES ES17735616T patent/ES2965017T3/es active Active
- 2017-06-06 AU AU2017277897A patent/AU2017277897B2/en active Active
-
2018
- 2018-11-21 ZA ZA2018/07852A patent/ZA201807852B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7195934B2 (ja) | 2022-12-26 |
| EP3463325B1 (en) | 2023-11-08 |
| WO2017212249A1 (en) | 2017-12-14 |
| CA3096121A1 (en) | 2017-12-14 |
| MX2018014278A (es) | 2019-03-14 |
| GB201609940D0 (en) | 2016-07-20 |
| ZA201807852B (en) | 2023-05-31 |
| US20190175501A1 (en) | 2019-06-13 |
| KR102412212B1 (ko) | 2022-06-23 |
| US11369568B2 (en) | 2022-06-28 |
| EP3463325A1 (en) | 2019-04-10 |
| RU2018142841A (ru) | 2020-06-04 |
| RU2018142841A3 (enExample) | 2020-09-30 |
| CA3026743A1 (en) | 2017-12-14 |
| ES2965017T3 (es) | 2024-04-10 |
| FI3463325T3 (fi) | 2023-12-19 |
| JP2019517541A (ja) | 2019-06-24 |
| BR112018075221B1 (pt) | 2024-02-06 |
| DK3463325T3 (da) | 2024-01-02 |
| CA3026743C (en) | 2024-05-28 |
| KR20190016957A (ko) | 2019-02-19 |
| CA3096121C (en) | 2022-11-15 |
| CN109310654A (zh) | 2019-02-05 |
| BR112018075221A2 (pt) | 2019-03-19 |
| AU2017277897B2 (en) | 2022-09-08 |
| AU2017277897A1 (en) | 2018-12-20 |
| NZ748596A (en) | 2025-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201909949XA (en) | Targeted immunotolerance | |
| SG11201805072PA (en) | Nicotine powder delivery system | |
| SG11201810934TA (en) | Microparticles comprising a sulphur-containing compound | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201810423XA (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
| SG11201804915RA (en) | Methods for treating huntington's disease | |
| SG11201906891RA (en) | Methods for the administration of certain vmat2 inhibitors | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201804384UA (en) | Geometric configurations for gastric residence systems | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201803906PA (en) | Control of cellular redox levels | |
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201805204WA (en) | Nicotine particle capsule | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG11201809594WA (en) | Nicotine particles and compositions | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201903193WA (en) | Deodorant comprisng a zinc carboxylate salt and aluminium chlorohydrate | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201909825VA (en) | Hsp90 inhibitor oral formulations and related methods | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
| SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
| SG11201809875VA (en) | Compositions and methods for treating spinal muscular atrophy |